Sandoz hitches its wagon to biosimilars, predicting $3B in sales from pipeline products over next 5 years
Fierce Pharma
JUNE 8, 2023
Novartis’ generics and biosimilars unit Sandoz—soon to be spun off as a stand-alone company—has seen a decline | Novartis’ generics and biosimilars unit Sandoz—soon to be spun off as a stand-alone company—has seen a decline in revenue every year since 2016.
Let's personalize your content